Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: A review of available trial evidence

Journal of Hypertension

Volumn 32, Issue 9, 2014, Pages 1741-1750

  Zanchetti, Alberto ^a,b   Liu, Lisheng ^c,d   Mancia, Giuseppe ^a,e   Parati, Gianfranco ^a,e   Grassi, Guido ^e,f   Stramba Badiale, Marco ^a   Silani, Vincenzo ^a,b   Bilo, Grzegorz ^a   Corrao, Giovanni ^e   Zambon, Antonella ^e   Scotti, Lorenza ^e   Zhang, Xinhua ^d   Wang, Hayyan ^d   Zhang, Yuqing ^c,d   Zhang, Xuezhong ^c,d   Guan, Ting Rui ^d   Berge, Eivind ^g   Redon, Josep ^h   Narkiewicz, Krzysztof ⁱ   Dominiczak, Anna ^j   Nilsson, Peter ^k   Viigimaa, Margus ^l   Laurent, Stéphane ^m   Agabiti Rosei, Enrico ⁿ   Wu, Zhaosu ^o   Zhu, Dingliang ^p   Rodicio, José Luis ^q   Ruilope, Luis Miguel ^r   Martell Claros, Nieves ^s   Pinto, Fernando ^t   Schmieder, Roland E ^u   Burnier, Michel ^v   Banach, Maciej ^w   Cifkova, Renata ^x   Farsang, Csaba ^y   Konradi, Alexandra ^z   Lazareva, Irina ^aa   Sirenko, Yuriy ^ab   Dorobantu, Maria ^ac   Postadzhiyan, Arman ^ad   Accetto, Rok ^ae   Jelakovic, Bojan ^af   Lovic, Dragan ^ag   Manolis, Athanasios J ^ah   Stylianou, Philippos ^ai   Erdine, Serap ^aj   Dicker, Dror ^ak   Wei, Gangzhi ^al   Xu, Chengbin ^al   Xie, Hengge ^am   Coca, Antonio ^an   O'Brien, John ^ao   Ford, Gary ^ap   more..

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FUWAI HOSPITAL   (China)

^d Beijing Hypertension League Institute   (China)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f IRCCS MULTIMEDICA   (Italy)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF VALENCIA   (Spain)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k LUND UNIVERSITY   (Sweden)

^l TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

^m HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁿ UNIVERSITY OF BRESCIA   (Italy)

^o CAPITAL MEDICAL UNIVERSITY   (China)

^p Shanghai Key Laboratory of Hypertension Shanghai Institute of Hypertension   (China)

^q UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^r HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^s HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^t EPE   (Portugal)

^u UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^v LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^w MEDICAL UNIVERSITY OF LODZ   (Poland)

^x CHARLES UNIVERSITY   (Czech Republic)

^y St Imre Univ Teaching Hospital   (Hungary)

^z ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

^aa REPUBLICAN SCIENTIFIC AND PRACTICAL CENTRE CARDIOLOGY   (Belarus)

^ab STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^ac Emergency Hospital Bucharest   (Romania)

^ad UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^ae Dr Peter Drzai Hospital   (Slovenia)

^af KBC Zagreb   (Croatia)

^ag Clinic for Internal Medicine InterMedic   (Serbia)

^ah IASO GENERAL HOSPITAL   (Greece)

^ai NICOSIA GENERAL HOSPITAL   (Cyprus)

^aj ISTANBUL UNIVERSITY   (Turkey)

^ak HASHARON HOSPITAL   (Israel)

^al PEKING UNIVERSITY   (China)

^am Military General Hospital   (China)

^an UNIVERSITY OF BARCELONA   (Spain)

^ao UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ap OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

blood pressure; cognitive decline; low density lipoprotein cholesterol; primary prevention; secondary prevention; stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; IRBESARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VERAPAMIL; CHOLESTEROL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DIASTOLIC BLOOD PRESSURE; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; BLOOD; COGNITION; COGNITION DISORDERS; DRUG EFFECTS; HYPERCHOLESTEROLEMIA; MALE; PRIMARY PREVENTION; RECURRENT DISEASE; SECONDARY PREVENTION; STROKE;

BLOOD PRESSURE; CHOLESTEROL; CHOLESTEROL, LDL; COGNITION; COGNITION DISORDERS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SECONDARY PREVENTION; STROKE;

EID: 84906091341     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000253     Document Type: Review

References (74)

1. Murray CJ, Lopez A. The global burden of disease. Boston, MA: Harvard Univ Press; 2006
2. Ministry of Health China. China health statistics yearbook; 2010. Beijing: Peking Union Medical College Press; 2010
3. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, et al. Proportion of different subtypes of stroke in China. Stroke 2003; 34:2091-2096
4. Zhang XH, Guan TR, Mao JW, Liu LS. Disparity and its time trends in stroke mortality between urban and rural populations in China 1987 to 2001. Changing patterns and their implications for public health policy. Stroke 2007; 38:3139-3144
5. Di Carlo A, Baldereschi M, Gandolfo C, Candelise L, Ghetti A, Maggi S, et al. Stroke in an elderly population. Incidence and impact on survival and daily function. The Italian Longitudinal Study on Aging. Cerebrovasc Dis 2003; 16:141-150
6. Touzé E, Varenne O, Chatellier G, Peyrard S, Rothwell PM, Mas JL. Risk of myocardial infarction and vascular death after transient ischaemic attack and ischaemic stroke: A systematic review and meta-Analysis. Stroke 2005; 36:2748-2755
7. Giles M, Rothwell P. Substantial underestimation of the need for outpatient services for TIA and minor stroke. Age Ageing 2007; 36:676-680
8. Lewington S, Clarke R, Qizilbash N, Peto N, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-Analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913
9. ODonnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010; 376:112-123
10. Collins R, Peto R, MacMahon S, Herbert P, Fieback NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-Term reductions in blood pressure-overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838
11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-Analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:1665-1683
12. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what level should systolic blood pressure be lowered?. A critical reappraisal. J Hypertens 2009; 27:923-934
13. Zanchetti A. Blood pressure targets of antihypertensive treatment: Up and down the J-shaped curve. Eur Heart J 2010; 31:2837-2840
14. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762
15. ACCORD Study GroupCushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585
16. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, et al., for the PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: The PROGRESS trial. J Hypertens 2006; 24:1201-1208
17. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 2000; 321:412-419
18. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP. J-shaped relationship between blood pressure and mortality in hypertensive patients: New insights from a meta-Analysis of individual-patient data. Ann Intern Med 2002; 136:438-448
19. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al., Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16:2170-2179
20. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 2006; 144:884-893
21. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27:1360-1369
22. Okin PM, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB. Impact of lower achieved blood pressure on outcomes in hypertensive patients. J Hypertens 2012; 30:802-810
23. Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 2011; 306:2137-2144
24. Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, De Leeuw PW, et al. On-Treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med 2007; 167:1884-1891
25. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010; 31:2897-2908
26. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP, PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes?. Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE ITTIMI) 22 trial. Circulation 2010; 122:2142-2151
27. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressure compared with office blood pressure in the general population: Follow-up results from the PAMELA study. Circulation 2005; 111:1777-1783
28. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-Analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007; 370:1829-1839
29. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: Review and updated meta-Analysis of statins for stroke prevention. Lancet Neurol 2009; 8:453-463
30. Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681
31. Carter AB. Hypotensive therapy in stroke survivors. Lancet 1970; 1:485-489
32. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA 1974; 229:409-418
33. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993; 24:543-548
34. Eriksson S, Olofsson B-O, Wester P-O, for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995; 5:21-25
35. PATS Collaborating Group. Poststroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 1995; 108:710-717
36. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041
37. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225-1237
38. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357
39. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology. J Hypertens 2007; 25:1105-1187
40. The SPS3 Study Group. Blood pressure targets in patients with recent lacunar stroke: The SPS3 randomized trial. Lancet 2013; 382:507-515
41. Ankolekar S, Stokes L, Bath PMW. PODCAST: Prevention Of Decline in Cognition After Stroke Trial: A factorial randomised trial of blood pressure and lipid lowering [abstract]. 20th European Stroke Conference (ESC), Hamburg 24-27 May 2011. Basel, Switzerland: S. Karger AG; 2011
42. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischaemic attack. N Engl J Med 2006; 355:549-559
43. Vergouwen MD, De Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 2008; 39:497-502
44. Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: A quantitative modeling study. Stroke 2007; 38:1881-1885
45. Amarenco P, Goldstein LB, Messig M, ONeill BJ, Callahan A 3rd, Sillesen H, et al. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke 2009; 40:2486-2492
46. Rothwell PM, Algra A, Amarenco P. Medical treatment in acute and long-Term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 2011; 377:1681-1692
47. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the Systolic Hypertension in the Elderly Program. Arch Intern Med 1994; 154:2154-2160
48. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, et al. Prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Lancet 1998; 352:1347-1351
49. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J, PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163:1069-1075
50. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al., for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886
51. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVETCOG): A double-blind, placebo controlled trial. Lancet Neurol 2008; 7:683-689
52. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al., Prevention Regimen for Effectively Avoiding Second Strokes (PRo-FESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRo-FESS) trial: A double-blind, active and placebo-controlled study. Lancet Neurol 2008; 7:875-884
53. Birns J, Morris R, Donaldson N, Kalra L. The effects of blood pressure reduction on cognitive function: A review of effects based on pooled data from clinical trials. J Hypertens 2006; 24:1907-1914
54. Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, et al., SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005; 18:1052-1059
55. Saxby BK, Harrington F, Wesnes KA, McKeith IG, Ford GA. Candesartan and cognitive decline in older patients with hypertension: A substudy of the SCOPE trial. Neurology 2008; 70:1858-1866
56. Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, et al. Reninangiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: Analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 2011; 10:43-53
57. Staessen JA, Thijs L, Richart T, Odili AN, Birkenhäger WH. Placebocontrolled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 2011; 57:e6-e7
58. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi A-C, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: A network meta-Analysis. J Hypertens 2013; 31:1073-1082
59. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment (MoCA): A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53:695-699
60. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2009; 2:CD003160
61. Ligthart SA, Moll Van Charante EP, Van Gool WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: A systematic review. Vasc Health Risk Manag 2010; 6:775-785
62. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004; 117:823-829
63. Evans MA, Golomb BA. Statin-Associated adverse cognitive effects: Survey results from 171 patients. Pharmacother 2009; 29:800-811
64. Heart Protection Study collaborative group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: A randomised placebo controlled trial. Lancet 2002; 360:7-22
65. Trompet S, Van Vliet P, De Craen AJM, Jolles J, Buckley BM, Murphy MB, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 2010; 257:85-90
66. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010; 74:956-964
67. Simons M, Schwärzler F, Lütjohann D, von Bergmann K, Beyreuther K, Dichgans J, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimers disease: A 26-week randomized, placebocontrolled, double-blind trial. Ann Neurol 2002; 52:346-350
68. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease. Arch Neurol 2005; 62:753-757
69. Ovbiagele B, Saver JL. Cerebral white matter hyperintensities on MRI: Current concepts and therapeutic implications. Cerebrovasc Dis 2006; 22:83-90
70. Dufouil C, Chalmers J, Coskun O, Besançon V, Bousser MG, Guillon P, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112:1644-1650
71. Godin O, Tzourio C, Maillard P, Mazoyer B, Dufouil C. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: The Three-City (3C)-Dijon magnetic resonance imaging study. Circulation 2011; 123:266-273
72. Nakamura K, Oita J, Yamaguchi T. Nocturnal blood pressure dip in stroke survivors. A pilot study. Stroke 1995; 26:1373-1378
73. ten Dam VH, Van Den Heuvel DM, Van Buchem MA, Westendorp RG, Bollen EL, Ford I, et al. Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology 2005; 64:1807-1809
74. Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, et al. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: Design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. J Hypertens 2014; 32:1888-1897.